Home ETF List About

Portfolio Holdings Detail for ISIN IE00BHZPJ890
Stock Name / FundiShares MSCI USA ESG Enhanced UCITS ETF USD (Dist)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity Type
Entity LEI 549300ZP07LMR36K1T02
ETF TickerEEDG(GBP) LSE
ETF TickerEEDS(USD) LSE
ETF TickerEEDG.LS(GBP) CXE
ETF TickerEEDS.LS(USD) CXE
ETF TickerOM3L.DE(EUR) CXE
ETF TickerEEDG.L(GBP) LSE
ETF TickerEEDS.L(GBP) LSE

Holdings detail for BMRN

Stock NameBiomarin Pharmaceutical Inc
TickerBMRN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS09061G1013
LEINSLL8ITTRR0J5HEMR848

Show aggregate BMRN holdings

News associated with BMRN

BioMarin Pharmaceutical (NASDAQ:BMRN) Coverage Initiated at HC Wainwright
HC Wainwright assumed coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) in a note issued to investors on Monday, MarketBeat.com reports. The firm set a “neutral” rating and a $60.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 7.74% from the stock’s previous […] - 2025-09-10 03:13:10
Predicting the Next Rule Breaker Buyout
In this Motley Fool Money podcast, Motley Fool analyst Karl Thiel and contributors Rick Munarriz and Jason Hall dig into four growth stocks ripe for the acquiring. There's also two sides to Tesla's changing AI story and a new kind of stock quote game. - 2025-08-19 01:08:00
9,709 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Bought by Atria Wealth Solutions Inc.
Atria Wealth Solutions Inc. bought a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 9,709 shares of the biotechnology company’s stock, valued at approximately $686,000. Several other hedge funds and other institutional investors also […] - 2025-08-13 04:49:08
Natixis Advisors LLC Grows Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Natixis Advisors LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 68.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,226 shares of the biotechnology company’s stock after buying an additional 13,488 shares during the quarter. Natixis Advisors […] - 2025-08-08 07:20:44
Guggenheim Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its target price hoisted by investment analysts at Guggenheim from $101.00 to $106.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price objective indicates a potential upside of 78.27% from the company’s current […] - 2025-08-08 04:26:58
BMRN Makes Bullish Cross Above Critical Moving Average
In trading on Tuesday, shares of BioMarin Pharmaceutical Inc (Symbol: BMRN) crossed above their 200 day moving average of $63.38, changing hands as high as $63.97 per share. BioMarin Pharmaceutical Inc shares are currently trading up about 5.7% on the day. The chart below show - 2025-08-05 12:47:37
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $93.74 Average Target Price from Analysts
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-four research firms that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and eighteen have given a buy recommendation to the company. […] - 2025-08-05 02:55:15
Biomarin Pharmaceutical Q2 25 Earnings Conference Call At 4:30 PM ET
(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) will host a conference call at 4:30 PM ET on August 4, 2025, to discuss Q2 25 earnings results. - 2025-08-04 08:30:49
Signaturefd LLC Increases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Signaturefd LLC boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 19.1% during the 1st quarter, Holdings Channel reports. The institutional investor owned 2,191 shares of the biotechnology company’s stock after acquiring an additional 352 shares during the period. Signaturefd LLC’s holdings in BioMarin Pharmaceutical were worth $155,000 as of […] - 2025-07-21 05:36:50
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Nisa Investment Advisors LLC
Nisa Investment Advisors LLC lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 5.0% in the first quarter, Holdings Channel reports. The firm owned 4,572 shares of the biotechnology company’s stock after buying an additional 217 shares during the period. Nisa Investment Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $323,000 as […] - 2025-07-17 06:25:00
Cerity Partners LLC Raises Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Cerity Partners LLC raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 203.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 84,832 shares of the biotechnology company’s stock after acquiring an additional 56,897 shares during the period. […] - 2025-07-17 05:51:03
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $113.00
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective upped by JPMorgan Chase & Co. from $108.00 to $113.00 in a research report sent to investors on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock. Other equities analysts have also issued research reports about the […] - 2025-07-17 04:48:52
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Xponance Inc.
Xponance Inc. raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.6% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 31,877 shares of the biotechnology company’s stock after buying an additional 202 shares during the quarter. Xponance Inc.’s holdings in BioMarin Pharmaceutical were worth […] - 2025-07-15 07:02:50
D.A. Davidson & CO. Has $480,000 Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
D.A. Davidson & CO. lessened its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 9.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,788 shares of the biotechnology company’s stock after selling 746 shares during the quarter. D.A. Davidson […] - 2025-07-11 05:32:53
Brokerages Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) PT at $93.61
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The average 1 […] - 2025-07-11 02:56:50
Principal Financial Group Inc. Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Principal Financial Group Inc. lifted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 455,485 shares of the biotechnology company’s stock after purchasing an additional 1,549 shares during […] - 2025-07-08 06:26:49
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Sumitomo Mitsui Trust Group Inc.
Sumitomo Mitsui Trust Group Inc. lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.6% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 467,245 shares of the biotechnology company’s stock after selling 2,798 shares during the period. Sumitomo Mitsui Trust Group […] - 2025-07-03 06:13:02
Bessemer Group Inc. Has $327,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Bessemer Group Inc. reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 12.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,618 shares of the biotechnology company’s stock after selling 683 shares during the quarter. Bessemer Group Inc.’s […] - 2025-07-03 05:00:50
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. boosted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 12.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 97,261 shares of the biotechnology company’s stock after purchasing an additional 10,687 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in BioMarin Pharmaceutical were […] - 2025-06-30 05:06:50
Kentucky Retirement Systems Insurance Trust Fund Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 5,490 shares of the biotechnology company’s stock, valued at approximately $388,000. A number of other institutional investors have also […] - 2025-06-26 05:04:54
Kentucky Retirement Systems Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Kentucky Retirement Systems bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 12,890 shares of the biotechnology company’s stock, valued at approximately $911,000. Other hedge funds have also recently added to or reduced their stakes in the company. Farther Finance […] - 2025-06-25 05:40:49
Exchange Traded Concepts LLC Acquires 979 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Exchange Traded Concepts LLC boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 5.2% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,796 shares of the biotechnology company’s stock after acquiring an additional 979 shares during the quarter. Exchange Traded […] - 2025-06-19 04:58:54
Mn Services Vermogensbeheer B.V. Boosts Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Mn Services Vermogensbeheer B.V. increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 12.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 35,500 shares of the biotechnology company’s stock after buying an additional 3,800 shares during the period. Mn Services Vermogensbeheer […] - 2025-06-18 05:44:54
NorthCrest Asset Manangement LLC Acquires Shares of 4,885 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
NorthCrest Asset Manangement LLC acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,885 shares of the biotechnology company’s stock, valued at approximately $345,000. Other hedge funds and […] - 2025-06-16 05:36:54
UMB Bank n.a. Increases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
UMB Bank n.a. grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 120.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,247 shares of the biotechnology company’s stock after acquiring an additional 1,228 shares during the period. UMB Bank […] - 2025-06-12 05:32:57
Gateway Investment Advisers LLC Cuts Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Gateway Investment Advisers LLC lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 22.2% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,512 shares of the biotechnology company’s stock after selling 1,003 shares during the period. Gateway Investment Advisers LLC’s […] - 2025-06-10 05:26:59
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high. But over the next two months, tariff-related unce - 2025-06-05 04:06:00
Tidal Investments LLC Sells 17,428 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Tidal Investments LLC lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 57.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,039 shares of the biotechnology company’s stock after selling 17,428 shares during the quarter. Tidal Investments LLC’s holdings in BioMarin […] - 2025-05-27 05:21:04
Quantinno Capital Management LP Purchases Shares of 5,848 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Quantinno Capital Management LP bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,848 shares of the biotechnology company’s stock, valued at approximately $384,000. A number […] - 2025-05-26 04:58:58
Analysts See 10% Upside For The Holdings of ILCB
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-19 07:58:34

iShares MSCI USA ESG Enhanced UCITS ETF USD (Dist) BMRN holdings

DateNumber of BMRN Shares HeldBase Market Value of BMRN SharesLocal Market Value of BMRN SharesChange in BMRN Shares HeldChange in BMRN Base ValueCurrent Price per BMRN Share HeldPrevious Price per BMRN Share Held
2025-09-29 (Monday)34,581USD 1,868,066USD 1,868,066
2025-09-26 (Friday)34,573USD 1,861,756USD 1,861,756
2025-09-25 (Thursday)34,981BMRN holding increased by 220USD 1,840,700BMRN holding decreased by -28399USD 1,840,700220USD -28,399 USD 52.62 USD 53.77
2025-09-24 (Wednesday)34,761USD 1,869,099USD 1,869,099
2025-09-18 (Thursday)33,233BMRN holding increased by 112USD 1,832,468BMRN holding increased by 31679USD 1,832,468112USD 31,679 USD 55.14 USD 54.37
2025-09-17 (Wednesday)33,121BMRN holding increased by 172USD 1,800,789BMRN holding increased by 23520USD 1,800,789172USD 23,520 USD 54.37 USD 53.94
2025-09-16 (Tuesday)32,949USD 1,777,269BMRN holding increased by 26359USD 1,777,2690USD 26,359 USD 53.94 USD 53.14
2025-09-15 (Monday)32,949USD 1,750,910USD 1,750,910
2025-09-12 (Friday)32,861USD 1,777,451USD 1,777,451
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of BMRN by Blackrock for IE00BHZPJ890

Show aggregate share trades of BMRN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-25BUY220 52.620* 62.98
2025-09-18BUY112 55.140* 63.03
2025-09-17BUY172 54.370* 63.08
2025-09-11SELL-216 55.910* 63.17 Profit of 13,645 on sale
2025-09-10BUY40 54.500* 63.22
2025-09-09BUY52 55.690* 63.27
2025-08-27BUY32 58.660* 63.33
2025-08-21BUY8 58.070* 63.39
2025-08-19BUY24 57.310* 63.46
2025-07-21BUY4 56.560* 63.50
2025-07-18BUY188 57.290* 63.54
2025-07-17BUY24 58.370* 63.57
2025-07-16BUY372 58.390* 63.60
2025-07-15BUY220 56.620* 63.64
2025-07-03SELL-32 57.500* 63.72 Profit of 2,039 on sale
2025-07-02SELL-248 57.170* 63.76 Profit of 15,813 on sale
2025-06-30SELL-4 54.970* 63.82 Profit of 255 on sale
2025-06-27BUY16 55.170* 63.88
2025-06-26BUY8 54.100* 63.94
2025-06-25BUY16 54.140* 64.00
2025-06-24SELL-12 54.690* 64.06 Profit of 769 on sale
2025-06-17SELL-16 55.000* 64.38 Profit of 1,030 on sale
2025-06-13SELL-8 56.220* 64.49 Profit of 516 on sale
2025-06-12BUY12 57.280* 64.54
2025-06-06SELL-56 56.650* 64.75 Profit of 3,626 on sale
2025-06-05SELL-88 55.270* 64.82 Profit of 5,704 on sale
2025-06-04SELL-116 56.110* 64.88 Profit of 7,527 on sale
2025-06-03BUY24 56.790* 64.94
2025-06-02SELL-8 57.050* 65.00 Profit of 520 on sale
2025-05-30BUY44 58.070* 65.05
2025-05-29SELL-24 58.550* 65.10 Profit of 1,562 on sale
2025-05-28SELL-16 58.090* 65.15 Profit of 1,042 on sale
2025-05-23SELL-72 57.550* 65.32 Profit of 4,703 on sale
2025-05-22BUY4 58.010* 65.38
2025-05-21SELL-20 58.480* 65.44 Profit of 1,309 on sale
2025-05-20BUY88 59.930* 65.48
2025-05-16SELL-36 59.270* 65.58 Profit of 2,361 on sale
2025-05-15BUY4 58.270* 65.64
2025-05-14BUY72 58.700* 65.69
2025-05-13BUY268 59.780* 65.74
2025-05-12BUY212 61.370* 65.78
2025-05-09BUY68 58.860* 65.83
2025-05-08SELL-64 59.820* 65.89 Profit of 4,217 on sale
2025-05-07BUY188 59.320* 65.94
2025-05-06BUY44 59.640* 65.99
2025-05-02SELL-8 62.030* 66.06 Profit of 529 on sale
2025-05-01SELL-4 62.710* 66.09 Profit of 264 on sale
2025-04-28SELL-544 62.980* 66.17 Profit of 35,995 on sale
2025-04-25SELL-8 63.300* 66.19 Profit of 530 on sale
2025-04-24SELL-124 62.740* 66.23 Profit of 8,212 on sale
2025-04-23SELL-44 61.940* 66.27 Profit of 2,916 on sale
2025-04-22SELL-28 61.500* 66.31 Profit of 1,857 on sale
2025-04-16SELL-156 58.820* 66.60 Profit of 10,389 on sale
2025-04-11BUY76 56.820* 66.83
2025-04-10BUY24 56.320* 66.93
2025-04-09BUY40 59.430* 67.01
2025-04-08SELL-116 55.890* 67.13 Profit of 7,787 on sale
2025-04-07BUY76 59.160* 67.21
2025-04-04BUY172 60.260* 67.28
2025-04-02BUY68 68.320* 67.27
2025-04-01BUY32 67.940* 67.26
2025-03-31SELL-172 70.690* 67.23 Profit of 11,563 on sale
2025-03-28SELL-16 71.440* 67.18 Profit of 1,075 on sale
2025-03-26BUY4 71.480* 67.07
2025-03-25BUY12 71.530* 67.02
2025-03-24BUY24 71.990* 66.96
2025-03-21BUY616 71.240* 66.91
2025-03-20BUY8 71.600* 66.86
2025-03-19SELL-116 71.320* 66.80 Profit of 7,749 on sale
2025-03-17SELL-8 71.550* 66.69 Profit of 533 on sale
2025-03-14SELL-16 69.440* 66.65 Profit of 1,066 on sale
2025-03-13SELL-4 70.600* 66.60 Profit of 266 on sale
2025-03-12SELL-22 70.540* 66.55 Profit of 1,464 on sale
2025-03-11BUY4 70.490* 66.50
2025-03-06BUY248 71.210* 66.29
2025-03-05SELL-20 71.190* 66.22 Profit of 1,324 on sale
2025-03-03BUY12 71.020* 66.10
2025-02-28BUY84 71.160* 66.03
2025-02-27SELL-80 69.120* 65.98 Profit of 5,279 on sale
2025-02-26SELL-1,012 68.810* 65.94 Profit of 66,733 on sale
2025-02-25SELL-68 71.170* 65.86 Profit of 4,479 on sale
2025-02-24BUY100 69.005* 65.82
2025-02-21BUY52 68.250* 65.78
2025-02-20BUY9 68.730* 65.74
2025-02-19BUY8 65.610* 65.74
2025-02-18SELL-44 64.860* 65.75 Profit of 2,893 on sale
2025-02-14BUY12 64.850* 65.78
2025-02-13SELL-8 64.420* 65.80 Profit of 526 on sale
2025-02-12SELL-152 65.860* 65.80 Profit of 10,002 on sale
2025-02-06BUY20 64.340* 65.95
2025-02-05SELL-60 64.185* 65.98 Profit of 3,959 on sale
2025-02-03BUY7 62.440* 66.11
2025-01-30SELL-84 63.880* 66.21 Profit of 5,561 on sale
2025-01-28SELL-52 63.250* 66.32 Profit of 3,449 on sale
2025-01-27BUY24 61.800* 66.42
2025-01-24BUY44 61.730* 66.52
2025-01-23BUY44 62.190* 66.62
2024-12-09BUY8 66.810* 66.62
2024-12-06BUY124 66.740* 66.62
2024-12-04BUY92 66.510* 66.63
2024-12-03BUY52 63.190* 66.72
2024-12-02BUY120 65.040* 66.76
2024-11-29BUY12 66.030* 66.78
2024-11-27BUY4 65.420* 66.86
2024-11-26SELL-136 64.880* 66.92 Profit of 9,101 on sale
2024-11-25BUY15,232 65.090* 66.97
2024-11-22SELL-4 64.260* 67.06 Profit of 268 on sale
2024-11-21BUY84 63.450* 67.18
2024-11-19SELL-18 61.970* 67.51 Profit of 1,215 on sale
2024-11-18BUY38 61.930* 67.71
2024-11-12BUY2 66.130* 67.77
2024-11-08BUY6 67.070* 67.89
2024-11-08BUY6 67.070* 67.89
2024-11-07BUY154 66.940* 67.98
2024-11-07BUY154 66.940* 67.98
2024-11-06BUY4 66.150* 68.16
2024-11-06BUY4 66.150* 68.16
2024-11-05SELL-10 66.040* 68.39 Profit of 684 on sale
2024-11-05SELL-10 66.040* 68.39 Profit of 684 on sale
2024-11-04SELL-72 66.010* 68.69 Profit of 4,946 on sale
2024-11-04SELL-72 66.010* 68.69 Profit of 4,946 on sale
2024-11-01SELL-20 66.600* 68.99 Profit of 1,380 on sale
2024-11-01SELL-20 66.600* 68.99 Profit of 1,380 on sale
2024-10-31BUY12 65.890* 69.51
2024-10-31BUY12 65.890* 69.51
2024-10-30SELL-76 66.680* 70.07 Profit of 5,325 on sale
2024-10-30SELL-76 66.680* 70.07 Profit of 5,325 on sale
2024-10-29SELL-72 69.910* 70.11 Profit of 5,048 on sale
2024-10-29SELL-72 69.910* 70.11 Profit of 5,048 on sale
2024-10-28BUY6 70.130* 70.11
2024-10-28BUY6 70.130* 70.11
2024-10-25BUY128 69.730* 70.30
2024-10-25BUY128 69.730* 70.30
2024-10-24BUY16 70.390* 70.26
2024-10-23SELL-4 69.980* 70.40 Profit of 282 on sale
2024-10-22BUY14 70.530* 70.28
2024-10-21SELL-140 70.280* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of BMRN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19410,0268,500779,51352.6%
2025-09-18309,9349,272546,27156.7%
2025-09-17792,001761,198,91966.1%
2025-09-16481,50501,174,96941.0%
2025-09-15537,10968901,19259.6%
2025-09-12559,51941804,63869.5%
2025-09-11479,992858740,03264.9%
2025-09-10670,394301865,41977.5%
2025-09-09347,7870583,41259.6%
2025-09-08440,4270726,53560.6%
2025-09-05291,8700466,53662.6%
2025-09-04516,7790829,87862.3%
2025-09-03280,8020490,76857.2%
2025-09-02312,7570686,20245.6%
2025-08-29214,12613370,04357.9%
2025-08-28251,9167439,79557.3%
2025-08-27370,3496578,90564.0%
2025-08-26289,675233549,90452.7%
2025-08-25355,827100585,45360.8%
2025-08-22357,18416556,52864.2%
2025-08-21352,5011,525524,29367.2%
2025-08-20339,77774602,58956.4%
2025-08-19220,4370499,04144.2%
2025-08-18330,939435644,69651.3%
2025-08-15498,8220931,91353.5%
2025-08-14241,4360529,66845.6%
2025-08-13719,9923501,132,11263.6%
2025-08-12217,2424606,98935.8%
2025-08-11336,9850722,60446.6%
2025-08-08574,538391,320,70843.5%
2025-08-07387,50431837,24046.3%
2025-08-06571,71843896,31463.8%
2025-08-051,685,68712,5033,542,20047.6%
2025-08-041,579,75703,686,25742.9%
2025-08-01716,52602,200,77732.6%
2025-07-31549,45938925,08459.4%
2025-07-30718,573101,234,75558.2%
2025-07-29226,72575481,37547.1%
2025-07-28243,6265412,92959.0%
2025-07-25247,29586445,58755.5%
2025-07-24380,699137586,87264.9%
2025-07-23251,7130450,21955.9%
2025-07-22387,886114638,28360.8%
2025-07-21228,3756,803346,20866.0%
2025-07-18292,003100575,02850.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.